Contents

Search

HER2/neu in tissue; HER2/Neu (erbB2) protein expression (H2N Oncosite)

Indications: - breast cancer Pathology: - overexpression of HER2 (at protein level) in 25% of breast cancer - overexpression predicts more aggressive disease Laboratory: - ~20% of tests for HER2 protein expression - LOINC: 18474-7, 31150-6, 32996-1, 42914-2, 48675-3, 48676-1, 49683-6, 51981-9 Methods: - in-situ hybridization - fluorescent in-situ hybridization (FISH) - immunohistochemistry

Related

receptor tyrosine-protein kinase erbB-2; p185erbB2; C-erbB-2; NEU proto-oncogene; tyrosine kinase-type cell surface receptor HER2; MLN 19; CD340 (ERBB2, HER2, NEU, NGL)

Specific

HER2/NEU in breast cancer specimen HER2/neu in serum

General

protein/peptide testing protein in tissue

References

  1. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2010) 2010 National Comprehensive Cancer Network, Inc.
  2. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. PMID: 17159189 Corresponding NGC guideline withdrawn Dec 2012
  3. ARUOP consult: ERBB2 (HER2/neu) (HercepTest) Testing https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing - HercepTest Tissue Assay, Paraffin Laboratory Test Directory ARUP: 49174
  4. Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013 Nov 1; 31:3997 PMID: 24101045 http://jco.ascopubs.org/content/31/31/3997